HCW Biologics reported a Q1 2026 EPS of $0.37, beating the expected loss of $0.44 per share, and revenue rose to $6.54 million from $5.06 million a year earlier, driven mainly by a licensing agreement with Beijing Trimmune Biotech. Shares surged 122.55% in after-hours trading following the earnings release. The company is advancing a Phase 1 trial for HCW9302, an immunotherapeutic for alopecia areata, with positive early results and a full data readout expected in Q4 2026. Despite strong quarterly performance, HCW Biologics faces financial risks including a low current ratio, significant debt, and doubts about its ability to continue without additional funding.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
Bitcoin and Ethereum experienced combined outflows exceeding $59 million as traders moved funds into stablecoins like USDT and fiat currencies, signaling a cautious stance in the crypto market. This rotation reflects a short-term defensive strategy, ...
Whales have accumulated 70 million XRP over the past week, showing strong confidence despite XRP's price consolidating below resistance levels. The XRP Ledger surpassed 8 million activated accounts, indicating growing network adoption across payments...
